Telephone: 415-476-2227; FAX: 415-476-0659
Risk of advanced fibrosis with grafts from hepatitis C antibody–positive donors: A multicenter cohort study†
Article first published online: 22 APR 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 18, Issue 5, pages 532–538, May 2012
How to Cite
Lai, J. C., O'Leary, J. G., Trotter, J. F., Verna, E. C., Brown, R. S., Stravitz, R. T., Duman, J. D., Forman, L. M., Terrault, N. A. and for the Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C) (2012), Risk of advanced fibrosis with grafts from hepatitis C antibody–positive donors: A multicenter cohort study. Liver Transpl, 18: 532–538. doi: 10.1002/lt.23396
Conflicts of Interest: Dr. O'Leary advises and is on the speakers' bureau for Vertex. She also advises Bristol Meyers Squibb. This study was supported by the National Institutes of Health (grant T32 DK060414 to Jennifer C. Lai) and the University of California San Francisco Liver Center (grant P30 DK026743 to Jennifer C. Lai and Norah A. Terrault).
- Issue published online: 22 APR 2012
- Article first published online: 22 APR 2012
- Accepted manuscript online: 23 JAN 2012 07:32AM EST
- Manuscript Accepted: 1 JAN 2012
- Manuscript Received: 21 AUG 2011
Over the last decade, the use of liver grafts from hepatitis C virus antibody–positive donors [HCV(+)Ds] has tripled in the United States. Although previous studies have demonstrated no association between an HCV(+)D status and graft loss, the effects of an HCV(+)D on histological outcomes are not well known. Hepatitis C virus (HCV)–infected recipients at 5 US centers (2002-2007) who survived more than 30 days with 1 or more posttransplant biopsy samples were included. Cox regression was used to examine the association between an HCV(+)D status and advanced fibrosis (stage 3/4 or higher). Ninety-nine of the 1206 patients (8%) received an HCV(+)D graft. Recipients of HCV(+)D grafts were older than recipients of hepatitis C virus antibody–negative donor [HCV(−)D] grafts (P = 0.03), but they were otherwise similar. HCV(+)D grafts were significantly lower in quality according to the donor risk index (P < 0.001). Advanced fibrosis occurred in 32% of HCV(+)D graft recipients and in 28% of HCV(−)D graft recipients (P = 0.39). The unadjusted 1- and 3-year rates of advanced fibrosis were significantly higher for HCV(+)D graft recipients (14% and 48%) versus HCV(−)D graft recipients (7% and 33%, P = 0.01). Transplantation with HCV(+)D grafts was associated with a 58% increased risk of advanced fibrosis [95% confidence interval (CI) = 1.05-2.36, P = 0.03]. However, in an analysis stratified by the mean donor age of 45 years, an HCV(+)D status was associated with advanced fibrosis only with donors >45 years old [hazard ratio (HR) = 1.76, 95% CI = 1.06-2.93, P = 0.03] and not with donors ≤45 years old (HR = 0.94, 95% CI = 0.47-1.87, P = 0.85). In conclusion, a careful consideration of the risks and benefits is needed with HCV(+)D grafts. Recipients of HCV(+)D grafts (especially from older donors) should undergo close monitoring for more rapidly progressive fibrosis. Studies are needed to determine whether early HCV therapy modifies this risk. Liver Transpl, 2012. © 2012 AASLD.